Etravirine: A novel nonnucleoside reverse transcriptase inhibitor for managing human immunodeficiency virus infection

American Journal of Health-System Pharmacy

Volumn 67, Issue 3, 2010, Pages 193-205

  Elsayed, Raghda K ^a   Caldwell, David J ^b  

^a UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^b UNIVERSITY OF LOUISIANA AT MONROE   (United States)

Author keywords

Antiretroviral agents; Dosage; Drug interactions; Etravirine; HIV infections; Mechanism of action; Resistance; Toxicity

Indexed keywords

ABACAVIR; ABACAVIR PLUS EMTRICITABINE; ABACAVIR PLUS LAMIVUDINE; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; DARUNAVIR; DARUNAVIR PLUS RITONAVIR; DELAVIRDINE; DIDANOSINE; DIDANOSINE PLUS LAMIVUDINE; EFAVIRENZ; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENFUVIRTIDE; ETRAVIRINE; FOSAMPRENAVIR; FOSAMPRENAVIR PLUS RITONAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PLACEBO; RITONAVIR; RITONAVIR PLUS SAQUINAVIR; SAQUINAVIR; TENOFOVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PYRIDAZINE DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ABNORMAL DREAMING; ACQUIRED IMMUNE DEFICIENCY SYNDROME; AMYLASE BLOOD LEVEL; ANEMIA; AREA UNDER THE CURVE; BILIRUBIN BLOOD LEVEL; CANNABINOID TEST; CD4+ T LYMPHOCYTE; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DNA RNA HYBRIDIZATION; DNA SYNTHESIS; DOSE KIDNEY FUNCTION RELATION; DOSE LIVER FUNCTION RELATION; DROWSINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXCRETION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENZYME ACTIVITY; ERYTHEMA MULTIFORME; FATIGUE; GENE MUTATION; GENETIC RESISTANCE; GENOTYPE; HALLUCINATION; HEADACHE; HEART DISEASE; HEMARTHROSIS; HEMATEMESIS; HEMOLYTIC ANEMIA; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INSOMNIA; LIPID BLOOD LEVEL; LIVER FUNCTION TEST; MAXIMUM PLASMA CONCENTRATION; MENTAL DISEASE; NAUSEA; NECROSIS; PANCREATITIS; PANCYTOPENIA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; PRIORITY JOURNAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SIDE EFFECT; SOMNOLENCE; STEVENS JOHNSON SYNDROME; STROKE; TOXIC EPIDERMAL NECROLYSIS; VIRUS LOAD; VIRUS REPLICATION; VIRUS RESISTANCE; ANTIVIRAL RESISTANCE;

ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HUMANS; PYRIDAZINES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 77449096726     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp080559     Document Type: Review

References (72)

1. Joint United Nations Programme on HIV/AIDS and World Health Organization. 2007 AIDS epidemic update: global overview. www.unaids.org/en (accessed 2008 Jul 20).
2. Centers for Disease Control and Prevention. HIV/AIDS surveillance report, 2006. www.cdc.gov/hiv/topics/surveillance/resources/reports (accessed 2009 Nov 17).
3. Haubrich R, Gubernick S, Yasothan U et al. Fresh from the pipeline: etravirine. Nat Rev. 2008; 7:287-8.
4. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf (accessed 2009 Feb 10).
5. Hammer SM, Eron JJ Jr, Reiss P et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA. 2008; 300:555-70.
6. BHIVA guidelines. BHIVA guidelines for the treatment of HIV-infected adults with antiretroviral therapy 2008: prepress version. www.bhiva.org/ cms1222226.asp (accessed 2008 Aug 1).
7. Rescriptor (delaviridine) package insert. New York: Pfizer; 2006 Jun.
8. Sustiva (efavirenz) package insert. Princeton, NJ: Bristol-Myers Squibb; 2008 Mar.
9. Viramune (nevirapine) package insert. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals; 2008 Jun.
10. Intelence (etravirine) package insert. Raritan, NJ: Tibotec Therapeutics; 2008 Jan.
11. Riddler SA, Haubrich R, DiRienzo AG et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med. 2008; 358:2095-106. (Pubitemid 351679596)
12. Lucas GM, Chaisson RE, Moore RD et al. Comparison of initial combination antiretroviral therapy with a single protease inhibitor, ritonavir and saquinavir, or efavirenz. AIDS. 2001; 15:1679-86. (Pubitemid 32918122)
13. Robbins GK, De Gruttola V, Shafer RW et al. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med. 2003; 349:2293-303.
14. Leth FV, Phanuphak P, Ruxrungtham K et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet. 2004; 363:1253-63. (Pubitemid 38496486)
15. Staszewski S, Morales-Ramirez J, Tashima KT et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med. 1999; 341:1865-73.
16. Intelence (etravirine) receives marketing authorisation in the European Union for HIV combination therapy. www.tibotec.com/news (accessed 2008 Sep 30).
17. Andries K, Azijn H, Thielemans T et al. TMC125, a novel next-generation non-nucleoside reverse transcriptase inhibitor active against reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2004; 4:437-46.
18. Vingerhoets J, Azijn H, Fransen E et al. TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments. J Virol. 2005; 79:12773-82. (Pubitemid 41433197)
19. De Corte BL. From 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk] (1,4)benzodiazepin-2(1H)-one (TIBO) to etravirine (TMC125): fifteen years of research on non-nucleoside inhibitors of HIV-1 reverse transcriptase. J Med Chem. 2005; 48:1689-96.
20. National Library of Medicine: ChemID-plus Advanced. Etravirine. www.chem.sis.nlm.nih.gov/chemidplus (accessed 2008 Jul 15).
21. Das K, Clark AD, Lewi PJ et al. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J Med Chem. 2004; 47:2550-60. (Pubitemid 38580092)
22. Flexner C. Antiretroviral agents and treatment of HIV infection. In: Brunton LL, Lazo JS, Parker KL, eds. Goodman and Gilman's the pharmacological basis of therapeutics. 11th ed. New York: McGraw-Hill; 2006:1273-5.
23. Grobler JA, Dornadula G, Rice MR et al. HIV-1 reverse transcriptase plus-strand initiation exhibits preferential sensitivity to non-nucleoside reverse transcriptase inhibitors in vitro. J Biol Chem. 2007; 282:8005-10. (Pubitemid 47093574)
24. Zdanowicz MM. The pharmacology of HIV drug resistance. Am J Pharm Educ. 2006; 70:1-9.
25. Figueiredo A, Moore KL, Mak J et al. Potent nonnucleoside reverse transcriptase inhibitors target HIV-1 Gag-Pol. PLoS Pathog. 2006; 2:e119.
26. Boffito M, Winston A, Jackson A et al. Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance. AIDS. 2007; 21:1449-55. (Pubitemid 46988005)
27. Kakuda TN, Schöller-Gyüre M, Workman C et al. Single- and multiple-dose pharmacokinetics of etravirine administered as two different formulations in HIV-1-infected patients. Antivir Ther. 2008; 13:655-61.
28. Lazzarin A, Campbell T, Clotet B et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet. 2007; 370:39-48. (Pubitemid 47017467)
29. Madruga JV, Cahn P, Grinsztejn B et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet. 2007; 370:29-38. (Pubitemid 47017466)
30. Kakuda TN, Schöller-Gyüre M, Peeters M et al. Pharmacokinetics of etravirine (ETR; TMC125) are not affected by sex, age, race, use of enfuvirtide (ENF) or treatment duration in HIV-1-infected subjects. Paper presented at 9th International Workshop on Clinical Pharmacology of HIV Therapy. New Orleans, LA; 2008 Apr.
31. Kakuda T, Wade J, Snoeck E et al. Pharmacokinetics and pharmacodynamics of the NNRTI TMC125 in treatment-experienced HIV-1-infected patients: pooled 24-week results of DUET-1 and DUET-2. Paper presented at 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA; 2008 Feb.
32. Vingerhoets J, Clotet B, Peeters M et al. Impact of baseline NNRTI mutations on the virological response to TMC125 (etravirine; ETR) in the DUET-1 and DUET-2 phase III clinical trials. Antivir Ther. 2007; 12(suppl):S34. Abstract.
33. Vingerhoets J, Peeters M, Azijn H et al. An update of the list of NNRTI mutations associated with decreased virologic response to etravirine (ETR): multivariate analyses on the pooled DUET-1 and DUET-2 clinical trial data. www.hivdb.stanford.edu/pages/pdf/ETR-poster-Vingerhoets-2008.pdf (accessed 2009 Oct 28).
34. Johnson VA, Brun-Vezinet F, Clotet B et al. Update of the drug resistance mutations in HIV-1: spring 2008. Top HIV Med. 2008; 16:62-8.
35. Llibre JM, Santos JR, Puig T et al. Prevalence of etravirine-associated mutations in clinical samples with resistance to nevirapine and efavirenz. J Antimicrob Chemother. 2008; 62:909-13.
36. Haubrich R, Schapiro J, Vingerhoets J et al. Combined darunavir (DRV) and etravirine (TMC125; ETR) resistance analysis of the pooled DUET trials: when can we spare the other new classes? Paper presented at 17th International AIDS Society Conference. Mexico City, Mexico; 2008 Aug 4.
37. Peeters M, Nijs S, Vingerhoets J et al. Determination of phenotypic clinical cutoffs for etravirine (ETR): pooled week 24 results of the DUET-1 and DUET-2 trials. Paper presented at 17th International Drug Resistance Workshop. Sitges, Spain; 2008 Jun.
38. Winters B, Villacian J, Van Craenenbroeck E et al. Development of vircoTYPE HIV-1 resistance analysis, including clinical cut-offs for TMC125, a new NNRTI. Paper presented at 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA; 2008 Feb 3.
39. Gazzard BG, Pozniak AL, Rosenbaum W et al. An open-label assessment of TMC 125 - a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance. AIDS. 2003; 17:F49-54.
40. Gruzdev B, Rakhmanova A, Doubovskaya E et al. A randomized, double-blind, placebo-controlled trial of TMC125 as 7-day monotherapy in antiretroviral naive, HIV-1 infected subjects. AIDS. 2003; 17:2487-94. (Pubitemid 38393321)
41. TMC125-C223 Writing Group, Nadler JP, Berger DS et al. Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis. AIDS. 2007; 21:F1-10.
42. Cohen C, Steinhart C, Ward D et al. Efficacy and safety results at 48 weeks with the novel NNRTI, TMC125, and impact of baseline resistance on the virologic response in study TMC125-C223. Paper presented at 16th International AIDS Society Conference. Toronto, Canada; 2006 Aug.
43. Woodfall B, Vingerhoets J, Peeters M et al. Impact of NNRTI and NRTI resistance on the response to the regimen of TMC125 plus two NRTIs in study TMC125-C227. Paper presented at 8th International Congress on Drug Therapy in HIV Infection. Glasgow, United Kingdom; 2006 Nov.
44. Levin J. Conference report: impact of NNRTI and NRTI resistance on the response to the regimen of TMC125 plus two NRTIs in study TMC125-C227. www.natap.org/2006/Glasgow/Glasgow-09.htm (accessed 2008 Aug 2).
45. Yazdanpanah Y, Fagard C, Descamps D et al. High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir in patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial. Clin Infect Dis. 2009; 49:1441-9.
46. Katlama C, Gatell JM, Molina JM et al. Pooled 24-week results of DUET-1 and DUET-2: efficacy of TMC125 (etravirine; ETR) in treatment-experienced HIV-1-infected patients. Paper presented at 11th European AIDS Conference. Madrid, Spain; 2007 Oct.
47. Kehr HA, Olin JL, Love BL. Etravirine: a non-nucleoside reverse transcriptase inhibitor for the treatment of resistant HIV-1 infection. Formulary. 2008; 43:105-14. (Pubitemid 351488250)
48. Haubrich R, Cahn P, Grinsztejn B et al. DUET-1: week 48 results of a phase III randomized double-blind trial to evaluate the efficacy and safety of TMC125 vs. placebo in 612 treatment-experienced HIV-I-infected patients. Paper presented at 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA; 2008 Feb.
49. Johnson M, Campbell T, Clotet B et al. DUET-2: week 48 results of a phase III randomized double-blind trial to evaluate the efficacy and safety of TMC125 vs. placebo in 591 treatment-experienced HIV-1-infected patients. Paper presented at 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA; 2008 Feb.
50. Trottier B, Johnson M, Katlama C et al. Pooled 48-week analysis of DUET-1 and DUET-2: durable efficacy and safety results of etravirine (ETR; TMC125) in treatment-experienced HIV-infected patients. Paper presented at 17th Annual Canadian Conference on HIV/AIDS Research. Montreal, Canada; 2008 Apr.
51. Picchio G, Vingerhoets J, Parkin N et al. Nucleoside-associated mutations cause hypersusceptibility to etravirine (ETR). Paper presented at 17th International Drug Resistance Workshop. Sitges, Spain; 2008 Jun.
52. Cahn P, Molina JM, Towner W et al. A 48-week pooled analysis of DUET-1 and DUET-2: the impact of baseline characteristics on virological response to etravirine (TMC125; ETR). Paper presented at 17th International AIDS Society Conference. Mexico City, Mexico; 2008 Aug 3.
53. Perri GD, Madruga JV, Sathasivam K et al. The impact of background regimen on virologic response to etravirine: pooled 48-week analysis of DUET-1 and DUET-2. Paper presented at 17th International AIDS Society Conference. Mexico City, Mexico; 2008 Aug 3.
54. Gatell J, Beatty G, Johnson M et al. Impact of TMC125, a next-generation NNRTI, on clinical outcomes (AIDS-defining illnesses and deaths): 24-week findings from a planned pooled analysis of the DUET studies. Paper presented at 11th European AIDS Conference. Madrid, Spain; 2007 Oct.
55. Hirschel B, Perneger T. No patient left behind - better treatments for resistant HIV infection. Lancet. 2007; 370:3-5. (Pubitemid 47017448)
56. Gebo K, Martin S, Corbett C et al. Impact of etravirine on hospitalizations and hospital-related costs: 48-week findings from pooled DUET trials. Paper presented at 17th International AIDS Society Conference. Mexico City, Mexico; 2008 Aug 3.
57. Towner W, Haigney Z, Sension MG et al. Efficacy, safety, and tolerability of etravirine with and without darunavir and/or raltegravir in treatment-experienced patients: preliminary analysis of TMC125-C214 Early Access Program (EAP) in the US. Paper presented at 17th International AIDS Society Conference. Mexico City, Mexico; 2008 Aug 3.
58. Raoof A, Lachau-Durand S, Verbeeck J et al. Etravirine has no effect on fetal development in rats and rabbits. Paper presented at 17th International AIDS Society Conference. Mexico City, Mexico; 2008 Aug 4.
59. Montaner J, Yeni P, Clumeck NN et al. Safety, tolerability, and preliminary efficacy of 48 weeks of etravirine therapy in a phase IIb dose-ranging study involving treatment-experienced patients with HIV-1 infection. Clin Infect Dis. 2008; 47:969-78.
60. Peeters M, Janssen K, Kakuda TN et al. Etravirine has no effect on QT and corrected QT interval in HIV-negative volunteers. Ann Pharmacother. 2008; 42:757-65.
61. Katlama C, Campbell T, Schechter M et al. Incidence and severity of nervous system and psychiatric events are similar with etravirine versus placebo: pooled 48-week data from the phase III DUET studies. Paper presented at 17th International AIDS Society Conference. Mexico City, Mexico; 2008 Aug 4.
62. Food and Drug Administration. Potential signals of serious risks/new safety information identified by the Adverse Event Reporting System (AERS), January-March 2008. www.fda.gov/Cder/aers/potential-signals/potential-signals- 2008Q1.htm (accessed 2009 Jan 12).
63. Data on file. Tibotec Therapeutics, Division of Ortho Biotech Products, L.P., Bridgewater, NJ; 2008.
64. Harris M, Zala C, Woodfall B et al. Pharmacokinetics and safety of adding TMC125 to stable regimens of saquinavir, lopinavir, ritonavir and NRTIs in HIV+ adults. Paper presented at 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO; 2006 Feb.
65. Benson CA, Kaplan JE, Masur H et al. Treating opportunistic infections among HIV-infected adults and adolescents. Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America. http://aidsinfo.nih.gov/contentfiles/TreatmentofOI- AA.pdf (accessed 2009 Feb 11).
66. Schöller-Gyüre M, Kakuda TN, De Smedt G et al. A pharmacokinetic study of etravirine (TMC125) co-administered with ranitidine and omeprazole in HIV-negative volunteers. Br J Clin Pharmacol. 2008; 66:508-16.
67. Schöller-Gyüre M, Kakuda TN, Van Solingen-Ristea RM et al. No clinically relevant effect of etravirine (ETR; TMC125) on digoxin pharmacokinetics in HIV-negative volunteers. Paper presented at 9th International Workshop on Clinical Pharmacology of HIV Therapy. New Orleans, LA; 2008 Apr.
68. ClinicalTrials.gov. TMC125-TiDP35-C213: safety and antiviral activity of etravirine (TMC125) in treatment-experienced, HIV infected children and adolescents. www.clinicaltrials.gov/ct2/results?term=etravirine (accessed 2008 Oct 1).
69. Kakuda TN, Königs C, Feiterna-Sperling C et al. Pharmacokinetics of the next-generation NNRTI etravirine (ETR; TMC125) in HIV-infected children between 6 and 17 years, inclusive. Paper presented at 17th International AIDS Society Conference. Mexico City, Mexico; 2008 Aug 3.
70. Ruxrungtham K, Pedro RJ, Latiff GH et al. Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor-naïve, nonnucleoside reverse transcriptase inhibitor-experienced patients: study TMC125-C227. HIV Med. 2008; 9:883-96.
71. ClinicalTrials.gov. Optimizing treatment for treatment-experienced, HIV-infected people. www.clinicaltrials.gov/ct2/results?term=etravirine (accessed 2008 Oct 1).
72. Di Biagio A, Bruzzone B, Rosso R et al. Successful rescue therapy with raltegravir (MK-0518) and etravirine (TMC125) in an HIV-infected patient failing all four classes of antiretroviral drugs. AIDS Patient Care STDS. 2008; 22:355-7. (Pubitemid 351735877)